The Trump administration has finalized a deal with drugmaker AbbVie to cut the cost of certain medicines, marking the latest pact as part of its “Most Favored Nation” pricing initiative.
(Reuters) - Cigna said on Monday it will remove AbbVie’s blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement in 2025, and recommend less pricey ...
Adalimumab is a medication used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, chronic psoriasis, hidradenitis suppurativa, and ...
Another major pharmacy benefit manager is adding Humira biosimilars to its formulary beginning next year. Express Scripts, which is part of Cigna's Evernorth subsidiary, said Monday that it will add ...
(Reuters) - AbbVie Inc is likely to beat Wall Street sales estimates for Humira in the second quarter as the only copycat in the U.S. market for the blockbuster arthritis drug struggled to gain ...
It’s been more than ten years since the FDA signed off on the United States’ first biosimilar product, opening up what was ...
Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy. As of today, July 1st, Cyltezo (adalimumab-adbm) is commercially ...
The arthritis drug Humira has been a blockbuster seller for more than two decades. Now, some copycats could end Humira's reign. The blockbuster drug Humira has been one of the world's top sellers for ...
(Reuters) - UnitedHealth Group said on Tuesday it will remove AbbVie’s blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement as of Jan. 1, 2025, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback